adamantane has been researched along with linagliptin in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 31 (83.78) | 24.3611 |
| 2020's | 6 (16.22) | 2.80 |
| Authors | Studies |
|---|---|
| Scheen, AJ | 3 |
| Gerich, J | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Jermendy, G | 2 |
| Derosa, G; Maffioli, P | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Bakris, GL; Flynn, C | 1 |
| Cohen, D | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Tibaldi, JM | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Hirata, T; Ito, T; Kurita, N; Shimizu, S; Uchihara, H | 1 |
| Camacho-Martinez, F; Martín-Gutierrez, FJ; Mendonça, FM; Ríos-Martín, JJ | 1 |
| Bingham-Gardiner, P; Bolodeoku, J; Hassan, SW; Lee, S; Scowcroft, A; Spencer, W; Tebboth, A | 1 |
| Cha, BS; Han, E; Kang, ES; Kim, BS; Kim, CS; Lee, BW; Lee, YH; Nam, JY; Park, SH | 1 |
| Chen, YW; Fu, CP; Lee, CL; Lee, IT; Lin, SY; Sheu, WH; Song, YM; Wang, JS | 1 |
| Everhart, D; Meah, Y; Rascati, KL; Worley, K | 1 |
| Dey, J | 1 |
| Lingvay, I | 1 |
| Antonenko, V; Curato, C; Dwi Putra, SE; Falke, LG; Hasan, AA; Hocher, B; Klein, T; Mohagheghi Samarin, A; Reichetzeder, C; Rippmann, J; Tsuprykov, O; von Websky, K | 1 |
| Brouillette, MA; Farahbakhshian, S; Kong, AM; Mukherjee, B; Pendergraft, T; Sheehan, JJ; Smith, DM | 1 |
| Abeni, D; Collina, MC; Di Zenzo, G; Didona, B; Fania, L; Mazzanti, C; Pagnanelli, G; Provini, A; Salemme, A | 1 |
| Bauer, E; Huang, H; Lang, K; Shetty, S | 1 |
| Alexander, GC; Baksh, SN; McAdams-DeMarco, M; Segal, JB | 1 |
| España, A; García-Díez, I; Hashimoto, T; Herrero-Gonzalez, JE; Iranzo, P; Ishii, N; Ivars-Lleó, M; López-Aventín, D; Pujol, RM | 1 |
| Bhutani, R; Bodla, RB; Kant, R; Kapoor, G | 1 |
| Helmy, MM; Mouneir, SM | 1 |
| Cheng, CY; Chiang, CP; Chien, WC; Chung, CH; Hung, CT; Liu, JS; Wang, WM | 1 |
| Azoulay, L; Bouganim, N; Platt, RW; Rouette, J; Yin, H; Yu, OHY | 1 |
| Andou, S; Hase, M; Ishizawa, F; Kishikawa, Y; Ojima, F; Sakurai, J; Satoh, J; Satoh, S; Takahashi, T | 1 |
| Hardman, TC; Hucke, O; Klein, T; Nar, H; Schnapp, G | 1 |
| Aquilante, CL; Bilker, WB; Bloomgarden, ZT; Brensinger, CM; Dawwas, GK; Deo, R; Dhopeshwarkar, N; Flory, JH; Hennessy, S; Kimmel, SE; Leonard, CE; Soprano, SE | 1 |
| Cai, ZJ; Chen, T; Li, N; Lin, WQ; Liu, MB; Zheng, B | 1 |
16 review(s) available for adamantane and linagliptin
| Article | Year |
|---|---|
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
Dipeptidyl peptidase-4 inhibitors: 3 years of experience.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Purines; Pyrrolidines; Quinazolines; Randomized Controlled Trials as Topic; Vildagliptin | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Three Cases of Bullous Pemphigoid Associated with Dipeptidyl Peptidase-4 Inhibitors - One due to Linagliptin.
Topics: Adamantane; Aged; Aged, 80 and over; Dipeptidyl-Peptidase IV Inhibitors; Drug Eruptions; Female; Humans; Linagliptin; Male; Nitriles; Pemphigoid, Bullous; Pyrrolidines; Vildagliptin | 2016 |
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
Topics: Adamantane; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Linagliptin; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2017 |
SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
Topics: Adamantane; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Glucosides; Humans; Hypoglycemic Agents; Linagliptin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
21 other study(ies) available for adamantane and linagliptin
| Article | Year |
|---|---|
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
Idiosyncratic liver injury induced by vildagliptin with successful switch to linagliptin in a hemodialyzed diabetic patient.
Topics: Adamantane; Aged; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Nitriles; Purines; Pyrrolidines; Quinazolines; Renal Dialysis; Vildagliptin | 2014 |
Demographic and Clinical Characteristics of Patients With Type 2 Diabetes Mellitus Initiating Dipeptidyl Peptidase 4 Inhibitors: A Retrospective Study of UK General Practice.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; General Practice; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Nitriles; Piperidines; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Uracil; Vildagliptin | 2016 |
Efficacy of different dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters in patients with type 2 diabetes undergoing dialysis.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Humans; Kidney Failure, Chronic; Linagliptin; Lipids; Male; Middle Aged; Nitriles; Peritoneal Dialysis; Pyrrolidines; Renal Dialysis; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2016 |
Hemoglobin glycation index as a useful predictor of therapeutic responses to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
Topics: Adamantane; Adult; Aged; Biomarkers, Pharmacological; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Glycated Hemoglobin; Health Status Indicators; Humans; Linagliptin; Male; Middle Aged; Nitriles; Predictive Value of Tests; Prognosis; Pyrrolidines; Retrospective Studies; Sitagliptin Phosphate; Treatment Outcome; Vildagliptin | 2017 |
Adherence, Persistence, and Health Care Costs for Patients Receiving Dipeptidyl Peptidase-4 Inhibitors.
Topics: Adamantane; Aged; Aged, 80 and over; Diabetes Mellitus; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Health Care Costs; Humans; Hypoglycemic Agents; Insulin; Linagliptin; Male; Managed Care Programs; Medication Adherence; Middle Aged; Sitagliptin Phosphate | 2017 |
Head-to-head comparison of structurally unrelated dipeptidyl peptidase 4 inhibitors in the setting of renal ischemia reperfusion injury.
Topics: Adamantane; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Kidney; Linagliptin; Male; Molecular Structure; Nitriles; Pyrrolidines; Rats; Rats, Wistar; Reperfusion Injury; Sitagliptin Phosphate; Structure-Activity Relationship; Vildagliptin | 2017 |
Healthcare costs among adults with type 2 diabetes initiating saxagliptin or linagliptin: a US-based claims analysis.
Topics: Adamantane; Adult; Diabetes Mellitus, Type 2; Dipeptides; Female; Health Care Costs; Humans; Hypoglycemic Agents; Insurance Claim Review; Linagliptin; Male; Middle Aged; Retrospective Studies; United States | 2017 |
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors.
Topics: Adamantane; Aged; Aged, 80 and over; Autoantibodies; Autoantigens; Collagen Type XVII; Dipeptidyl-Peptidase IV Inhibitors; Epitopes; Female; Humans; Immunoglobulin A; Immunoglobulin E; Immunoglobulin G; Linagliptin; Male; Membrane Glycoproteins; Middle Aged; Nitriles; Non-Fibrillar Collagens; Pemphigoid, Bullous; Piperidines; Pyrrolidines; Sitagliptin Phosphate; Uracil; Vildagliptin | 2018 |
Concordance with prescribing information dosage recommendations for dipeptidyl-peptidase-4 inhibitors among type 2 diabetes mellitus patients with moderate to severe chronic kidney disease.
Topics: Adamantane; Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Hypoglycemic Agents; Linagliptin; Male; Middle Aged; Renal Insufficiency, Chronic; Retrospective Studies; Sitagliptin Phosphate | 2018 |
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients.
Topics: Adamantane; Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Bayes Theorem; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Heart Failure; Humans; Linagliptin; Male; Middle Aged; Piperidines; Practice Guidelines as Topic; Sitagliptin Phosphate; United States; United States Food and Drug Administration; Uracil | 2018 |
Bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitors. Eight cases with clinical and immunological characterization.
Topics: Adamantane; Aged; Aged, 80 and over; Autoantigens; Collagen Type XVII; Dipeptidyl-Peptidase IV Inhibitors; Dystonin; Female; Humans; Immunoglobulin G; Linagliptin; Male; Nitriles; Non-Fibrillar Collagens; Pemphigoid, Bullous; Phenotype; Pyrrolidines; Sitagliptin Phosphate; Vildagliptin | 2018 |
Optimization of a single HPLC-PDA method for quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin using central composite design.
Topics: Adamantane; Benzhydryl Compounds; Chromatography, High Pressure Liquid; Dipeptides; Dose-Response Relationship, Drug; Gliclazide; Glucosides; Linagliptin; Metformin; Molecular Structure; Pioglitazone; Pyrazoles; Software; Structure-Activity Relationship; Thiazolidines | 2019 |
Reno-protective effect of linagliptin against gentamycin nephrotoxicity in rats.
Topics: Adamantane; Animals; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gentamicins; Kidney; Kidney Diseases; Linagliptin; Male; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate | 2019 |
Increased risk of bullous pemphigoid in dipeptidyl peptidase 4 inhibitors: A nationwide, population-based, cohort study in Taiwan.
Topics: Adamantane; Adult; Age Factors; Aged; Case-Control Studies; Databases, Factual; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Incidence; Linagliptin; Male; Middle Aged; Pemphigoid, Bullous; Piperidines; Risk Factors; Sitagliptin Phosphate; Taiwan; Uracil; Vildagliptin; Young Adult | 2020 |
Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Topics: Adamantane; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Incidence; Incretins; Linagliptin; Liraglutide; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pulmonary Disease, Chronic Obstructive; Risk Factors; Sitagliptin Phosphate; Smoking | 2020 |
[Efficacy of Saxagliptin for Blood Glucose Control in Hemodialysis Patients with Diabetes].
Topics: Adamantane; Aged; Aged, 80 and over; Blood Glucose; Cost Savings; Diabetes Mellitus; Dipeptides; Drug Substitution; Female; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Linagliptin; Male; Middle Aged; Pilot Projects; Pyrazoles; Renal Dialysis; Serum Albumin; Thiazolidines | 2020 |
Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
Topics: Adamantane; Antiviral Agents; Coronavirus 3C Proteases; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Repositioning; Enzyme Assays; Heterocyclic Compounds; Linagliptin; Piperidines; SARS-CoV-2; Sitagliptin Phosphate; Uracil | 2021 |
Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors and Sudden Cardiac Arrest and Ventricular Arrhythmia: Population-Based Cohort Studies.
Topics: Adamantane; Administrative Claims, Healthcare; Aged; Arrhythmias, Cardiac; Cohort Studies; Databases, Factual; Death, Sudden, Cardiac; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Female; Humans; Kaplan-Meier Estimate; Linagliptin; Male; Middle Aged; Proportional Hazards Models; Sitagliptin Phosphate | 2022 |
Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
Topics: Adamantane; China; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Resistance; Drug Therapy, Combination; Humans; Linagliptin; Metformin; Middle Aged; Piperidines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Uracil; Vildagliptin | 2021 |